Is vcnx good buy

Vaccinex (VCNX) is not a good buy at the moment. Here's why:

1. Financial Performance: Vaccinex has reported a net loss of $5.63 million and a diluted EPS of$-3.1 as of Q2 2024. The company's revenue growth rate is 20.24%, but its net income growth rate is -5.44%, which indicates that the company is growing its top line, but struggling to translate that into profitability.

1/3

VCNX Total Revenue YoY, Total Revenue

2. Dividend Status: Vaccinex does not distribute dividends, making it an unsuitable option for income-focused investors.
3. Technical Indicators: The stock's technical indicators are mixed. The RSI is at 80.35, which is considered overbought and may indicate a potential pullback. However, the MACD is at 0.39, which could suggest a lack of momentum.

VCNX Trend

4. Market Sentiment and Fund Flow: The net fund flow is positive at $42,426.98, which could be a sign of investor confidence$. However, the net fund flow (block order) is negative at -13,103.96, which may indicate that large investors are selling the stock.

JNJ, MRNA, PFE, VCNX Net Fund Flow

5. Strategic Developments: Vaccinex has reported promising new efficacy data for its SIGNAL-AD Phase 1b/2 trial of pepinemab at the CTAD conference. However, the company is facing potential delisting from Nasdaq due to failing to meet the required minimum stockholders' equity. The company has also secured approximately $6.2 million in funding through the exercise of existing warrants and the issuance of new ones, which could support its ongoing development plans.

In conclusion, while Vaccinex has shown some positive developments, such as promising trial results and funding secured, the company's financial performance and technical indicators present significant concerns. The potential delisting risk and lack of dividend payments also make it a less attractive option. Therefore, Vaccinex is not a good buy at the moment.